Astellas Pharma Inc Unsponsored Adr News, Astellas Pharma Inc Unsponsored Adr Quote, ALPMY Quote

Astellas Pharma Inc Unsponsored Adr (OP:ALPMY) Delayed: 15.68 +0.20 (1.29%)

Prev. Close

$15.48

Today 6M 1Y 5Y

Open

$15.76

52 Wk High

$19.40

52 Wk Low

$12.50

Day High

$15.76

Day Low

$15.64

P/E

N/A

EPS

$0.00

Volume

53,987

Friends, Peers and Foes (?): 4503:JP, PFE, ISEE, SGEN, MTSFY (more...)

ALERTS | RSS

Oct 6, 2026 07:30 PM Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
Oct 2, 2026 08:00 AM New Preliminary Real-World VEOZAH™ (fezolinetant) Data Highlights Improvements in Menopause-Related Symptoms and Sleep Outcomes
Aug 24, 2026 07:30 PM Astellas begins Phase 3 trial of ASP2138 for gastric cancer
Aug 24, 2026 07:30 PM Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Aug 18, 2026 08:25 AM CLSA Starts Astellas Pharma Inc (4503:JP) (ALPMY) at Outperform (2)
Aug 17, 2026 02:31 AM Astellas Pharma Inc (4503:JP) (ALPMY) PT Raised to JPY2,500 at JPMorgan
Jun 29, 2026 08:29 AM Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,300 at JPMorgan
Jun 16, 2026 12:22 AM Goldman Sachs Reiterates Buy Rating on Astellas Pharma Inc (4503:JP) (ALPMY)
May 28, 2026 10:37 AM Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,600 at Macquarie
May 26, 2026 02:45 AM Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

Entities mentioned with ALPMY

View All Entities